
TARGET MARKET DETERMINATION

Made by: Melodiol Global Health Limited (ACN 609 406 911) of Suite 5, CPC, 145 Stirling Highway, Nedlands WA 6009 (**Company**)

Product: Options to acquire fully paid ordinary shares in the Company (**Shares**) (**Options**) in connection with a non-renounceable entitlement bonus issue under a prospectus dated 31 October 2023 (**Prospectus**) (**Bonus Options**).

Effective date: 31 October 2023

This target market determination (**TMD**) has been prepared by the Company in relation to an offer to issue the Bonus Options made by the Company under the Prospectus. A copy of the Prospectus is available on the Company's website, www.melodiolglobalhealth.com. The Company has not appointed a lead manager to the offer.

The offer will be made under, or accompanied by, a copy of the Prospectus. Any recipient of this TMD should carefully read and consider the Prospectus in full and consult their professional adviser if they have any questions regarding the contents of the Prospectus. As this is a bonus issue of options, Eligible Shareholders (defined below) are not required to apply for the Bonus Options and, as such, there is no application form attached to the Prospectus. There is no cooling off period in respect of the issue of the Bonus Options. This TMD is not a disclosure document for the purposes of the *Corporations Act 2001* (Cth), and therefore has not been lodged, and does not require lodgement, with the Australian Securities and Investments Commission (**ASIC**) nor does it contain a full summary of the terms and conditions of the Bonus Options.

This TMD does not take into account what you currently have, or what you want and need, for your financial future. It is important for you to consider these matters and read the Prospectus before you make an investment decision. The Company is not licensed to provide financial product advice in relation to the Bonus Options.

1. TARGET MARKET

Factor	Target market
Investment Objective	The Company expects that an investment in Bonus Options will be suitable to investors who wish to gain exposure to equities in a small-cap pharmaceutical, biotechnology & life sciences company listed on the Australian Securities Exchange (ASX).
Investment Timeframe	The target market of investors will take a medium to long term outlook on their investment. Investors with a short-term outlook for their investment will benefit from an anticipated listing of the Bonus Options on ASX, as well as an ability to exercise Bonus Options and trade the underlying Shares issued on exercise should the exercise price of the Bonus Options be lower than the trading price of Shares. Investors with a medium-term outlook will benefit from an ability to exercise the Bonus Options within the 5 year term of the Bonus Options and increase their shareholding and exposure to the potential upside in the Company's Shares into the future.

	<p>Given the need to pay the exercise price in order to acquire Shares, Investors in the target market are in a financial position that is sufficient for them to invest their funds over a 5 year time horizon should they wish to exercise their Bonus Options. Any decision to exercise the Bonus Options is likely to be based on the trading price of the Shares.</p>
Investment Metrics	<p>While the Company does not have an established eligibility framework for investors based on metrics such as age, expected return or volatility, it is expected that the target market of investors will be able to withstand potential fluctuations in the value of their investment.</p> <p>An exercise price is required to be paid to acquire shares on exercise of Bonus Options. As such, the capacity to realise the underlying value of the Bonus Options would require that they be exercised on or before the expiry date. Investors in the target market will need to be in a financial position to have sufficient available funds so as to facilitate an exercise of the Bonus Options prior to the expiry date. Prior to the expiry date, investors' ability to liquidate the Bonus Options may be limited by a lack of liquidity in the trading of Bonus Options and Shares and the price of the Shares.</p> <p>The Bonus Options offer no guaranteed income or capital protection.</p>
Risk	<p>The Company considers that an investment in the Bonus Options is highly speculative, such that an investment in the Company is not appropriate for an investor who would not be able to bear a loss of some or all of the investment. Investors should also have a sufficient level of financial literacy and resources (either alone or in conjunction with an appropriate adviser) to understand and appreciate the risks of investing in Bonus Options as an asset class generally and the more specific risks of investing in an Australian listed pharmaceuticals, biotechnology and life sciences company.</p>

2. DISTRIBUTION CONDITIONS

The offer of Bonus Options under the Prospectus is being made to those shareholders in the Company registered at the record date specified in the Prospectus with a registered address in Australia, New Zealand, Germany, United States of America (Colorado) and Canada (British Columbia, Nova Scotia, Ontario and Alberta) (**Eligible Shareholders**).

The Prospectus will include jurisdictional conditions on eligibility. The Company will also include on its web landing page a copy of this TMD and the Prospectus. As the offer is a bonus issue of options to Eligible Shareholders, Eligible Shareholders are not required to apply for the Bonus Options and, as such, there is no application form attached to the Prospectus. This means that retail clients cannot meet the eligibility criteria of the expected target market outlined in this TMD if they do not have a registered address in Australia, New Zealand, Germany, United States of America (Colorado) and Canada (British Columbia, Nova Scotia, Ontario and Alberta).

The Company considers that these distribution conditions will ensure that persons who invest in Bonus Options fall within the target market in circumstances where personal advice is not being provided to those persons by the Company.

3. REVIEW TRIGGERS

The Bonus Options are being offered for a limited offer period set out in the Prospectus, after the conclusion of which the Bonus Options will no longer be available for investment by way of issue. It follows that the TMD will only apply in the period between the commencement of the offer of the Bonus Options and the issue of the Bonus Options shortly after the close of the Offer (**Offer Period**).

To allow the Company to determine whether circumstances exist that indicate this TMD is no longer appropriate to the Bonus Options and should be reviewed, the following review triggers apply for the Offer Period:

- (a) a new offer of Bonus Options that requires preparation of a disclosure document is made after completion of the Offer Period;
- (b) any event or circumstance that would materially change a factor taken into account in making this TMD;
- (c) the existence of a significant dealing of the Bonus Options that is not consistent with this TMD. The Company does not consider that an on-sale of the Bonus Options on market is a significant dealing;
- (d) ASIC raises concerns with the Company regarding the adequacy of the design or distribution of the Bonus Options or this TMD; and
- (e) material changes to the regulatory environment that applies to an investment in the Bonus Options.

4. REVIEW PERIOD

If a review trigger occurs during the Offer Period, the Company will undertake a review of the TMD in light of the review trigger.

The Company will otherwise complete a review of the TMD immediately prior to the issue of Bonus Options under the Offer.

5. INFORMATION REPORTING

The reporting requirements of all distributors is set out in the table below.

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
Whether the distributor received complaints about the Bonus Options.	<ul style="list-style-type: none"> • For such time as the Offer Period remains open, within 10 business days after the end of each quarter. • Within 10 business days after the end of the Offer Period. 	<ul style="list-style-type: none"> • The number of complaints received. • A summary of the nature of each complaint or a copy of each complaint.

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
A significant dealing of the Bonus Options that is not consistent with this TMD	As soon as reasonably practicable after the significant dealing occurs, but in any event no later than 10 business days after the significant dealing occurs.	<ul style="list-style-type: none"> • Details of the significant dealing. • Reasons why the distributor considers that the significant dealing is not consistent with this TMD.
A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.	Within 10 business days after the end of the close of the offer of Bonus Options in accordance with the Prospectus.	A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.

6. CONTACT DETAILS

Contact details in respect of this TMD for the Company are:

Erlyn Dawson
Joint Company Secretary
Phone: +61 8 9389 3180
Email: info@cresopharma.com

TARGET MARKET DETERMINATION

Made by: Melodiol Global Health Limited (ACN 609 406 911) of Suite 5, CPC, 145 Stirling Highway, Nedlands WA 6009 (**Company**)

Product: Free attaching options to acquire fully paid ordinary shares in the Company (**Shares**) (**Options**) to specific participants in connection with a placement of Shares to convert outstanding debt into securities, under a prospectus dated 31 October 2023 (**Prospectus**) (**ME1OD Options**)

Effective date: 31 October 2023

This target market determination (**TMD**) has been prepared by the Company in relation to an offer to issue the ME1OD Options made by the Company under the Prospectus. A copy of the Prospectus is available on the Company's website, www.melodiolglobalhealth.com. The Company has not appointed a lead manager to the offer.

The offer will be made under, or accompanied by, a copy of the Prospectus. Any recipient of this TMD should carefully read and consider the Prospectus in full and consult their professional adviser if they have any questions regarding the contents of the Prospectus. Any recipient of this TMD who wants to acquire ME1OD Options under the offer will need to complete the application form that will be in, or will accompany, the Prospectus. There is no cooling off period in respect of the issue of the ME1OD Options. This TMD is not a disclosure document for the purposes of the *Corporations Act 2001* (Cth), and therefore has not been lodged, and does not require lodgement, with the Australian Securities and Investments Commission (**ASIC**) nor does it contain a full summary of the terms and conditions of the ME1OD Options

This TMD does not take into account what you currently have, or what you want and need, for your financial future. It is important for you to consider these matters and read the Prospectus before you make an investment decision. The Company is not licensed to provide financial product advice in relation to the ME1OD Options.

1. TARGET MARKET

Factor	Target market
Investment Objective	The Company expects that an investment in ME1OD Options will be suitable to investors who wish to gain exposure to equities in a small-cap pharmaceutical, biotechnology & life sciences company listed on the Australian Securities Exchange (ASX).
Investment Timeframe	The target market of investors will take a short to medium term outlook on their investment. Investors with a short-term outlook for their investment will benefit from an anticipated listing of the ME1OD Options on ASX, as well as ability to exercise ME1OD Options and trade the underlying Shares issued on exercise should the exercise price of the ME1OD Options be lower than the trading price of Shares. Investors with a medium-term outlook will benefit from an ability to exercise the ME1OD Options within the 3 year term of the ME1OD Options and increase their shareholding and exposure to the

	<p>potential upside in the Company's Shares into the future.</p> <p>Given the need to pay the exercise price in order to acquire Shares, Investors in the target market are in a financial position that is sufficient for them to invest their funds over a 3 year time horizon should they wish to exercise their ME1OD Options. Any decision to exercise the ME1OD Options is likely to be based on the trading price of the Shares.</p>
Investment Metrics	<p>While the Company does not have an established eligibility framework for investors based on metrics such as age, expected return or volatility, it is expected that the target market of investors will be able to withstand potential fluctuations in the value of their investment.</p> <p>An exercise price is required to be paid to acquire shares on exercise of ME1OD Options. As such, the capacity to realise the underlying value of the ME1OD Options would require that they be exercised on or before the expiry date. Investors in the target market will need to be in a financial position to have sufficient available funds so as to facilitate an exercise of the ME1OD Options prior to the expiry date. Prior to the expiry date, investors' ability to liquidate the ME1OD Options may be limited by a lack of liquidity in the trading of ME1OD Options and Shares and the price of the Shares.</p> <p>The ME1OD Options offer no guaranteed income or capital protection.</p>
Risk	<p>The Company considers that an investment in the ME1OD Options is highly speculative, such that an investment in the Company is not appropriate for an investor who would not be able to bear a loss of some or all of the investment. Investors should also have a sufficient level of financial literacy and resources (either alone or in conjunction with an appropriate adviser) to understand and appreciate the risks of investing in ME1OD Options as an asset class generally and the more specific risks of investing in an Australian listed in an Australian listed pharmaceuticals, biotechnology and life sciences company.</p>

2. DISTRIBUTION CONDITIONS

The offer of ME1OD Options Offer under the Prospectus is being made to service providers that agreed to convert their existing debt into securities as specified in the Prospectus (**Eligible Shareholders**).

Any entitlement not taken up under the offer will not be issued. Eligible Shareholders may only subscribe for the number of ME1OD Options as specified in the Prospectus.

The Prospectus will include jurisdictional conditions on eligibility. The Company will also include on its web landing page for the offer of ME1OD Options a copy of this TMD and require that retail clients confirm that they meet the eligibility criteria

of the expected target market outlined in this TMD before they apply for ME1OD Options.

The Company considers that these distribution conditions will ensure that persons who invest in ME1OD Options fall within the target market in circumstances where personal advice is not being provided to those persons by the Company.

3. REVIEW TRIGGERS

The ME1OD Options are being offered for a limited offer period set out in the Prospectus, after the conclusion of which the ME1OD Options will no longer be available for investment by way of issue. It follows that the TMD will only apply in the period between the commencement of the offer of the ME1OD Options and the issue of the ME1OD Options shortly after the close of the Offer (**Offer Period**).

To allow the Company to determine whether circumstances exist that indicate this TMD is no longer appropriate to the ME1OD Options and should be reviewed, the following review triggers apply for the Offer Period:

- (a) a new offer of ME1OD Options that requires preparation of a disclosure document is made after completion of the Offer Period;
- (b) any event or circumstance that would materially change a factor taken into account in making this TMD;
- (c) the existence of a significant dealing of the ME1OD Options that is not consistent with this TMD. The Company does not consider that an on-sale of the ME1OD Options on market is a significant dealing;
- (d) ASIC raises concerns with the Company regarding the adequacy of the design or distribution of the ME1OD Options or this TMD; and
- (e) material changes to the regulatory environment that applies to an investment in the ME1OD Options.

4. REVIEW PERIOD

If a review trigger occurs during the Offer Period, the Company will undertake a review of the TMD in light of the review trigger.

The Company will otherwise complete a review of the TMD immediately prior to the issue of ME1OD Options under the Offer.

5. INFORMATION REPORTING

The reporting requirements of all distributors is set out in the table below.

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
Whether the distributor received complaints about the ME1OD Options.	<ul style="list-style-type: none">• For such time as the Offer Period remains open, within 10 business days after the end of each quarter.	<ul style="list-style-type: none">• The number of complaints received.• A summary of the nature of each complaint or a copy of each complaint.

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
	<ul style="list-style-type: none"> Within 10 business days after the end of the Offer Period. 	
A significant dealing of the ME1OD Options that is not consistent with this TMD	As soon as reasonably practicable after the significant dealing occurs, but in any event no later than 10 business days after the significant dealing occurs.	<ul style="list-style-type: none"> Details of the significant dealing. Reasons why the distributor considers that the significant dealing is not consistent with this TMD.
A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.	Within 10 business days after the end of the close of the offer of ME1OD Options in accordance with the Prospectus.	A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.

6. CONTACT DETAILS

Contact details in respect of this TMD for the Company are:

Erlyn Dawson
Joint Company Secretary
Phone: +61 8 9389 3180
Email: info@cresopharma.com

TARGET MARKET DETERMINATION

Made by: Melodiol Global Health Limited (ACN 609 406 911) of Suite 5, CPC, 145 Stirling Highway, Nedlands WA 6009 (**Company**)

Product: Free attaching options to acquire fully paid ordinary shares in the Company (**Shares**) (**Options**) to specific participants in connection with a placement of Shares to convert outstanding debt into securities under a prospectus dated 31 October 2023 (**Prospectus**) (**Unquoted Options**)

Effective date: 31 October 2023

This target market determination (**TMD**) has been prepared by the Company in relation to an offer to issue the Unquoted Options made by the Company under the Prospectus. A copy of the Prospectus is available on the Company's website, www.melodiolglobalhealth.com. The Company has not appointed a lead manager to the offer.

The offer will be made under, or accompanied by, a copy of the Prospectus. Any recipient of this TMD should carefully read and consider the Prospectus in full and consult their professional adviser if they have any questions regarding the contents of the Prospectus. Any recipient of this TMD who wants to acquire Unquoted Options under the offer will need to complete the application form that will be in, or will accompany, the Prospectus. There is no cooling off period in respect of the issue of the Unquoted Options. This TMD is not a disclosure document for the purposes of the *Corporations Act 2001* (Cth), and therefore has not been lodged, and does not require lodgement, with the Australian Securities and Investments Commission (**ASIC**) nor does it contain a full summary of the terms and conditions of the Unquoted Options

This TMD does not take into account what you currently have, or what you want and need, for your financial future. It is important for you to consider these matters and read the Prospectus before you make an investment decision. The Company is not licensed to provide financial product advice in relation to the Unquoted Options.

1. TARGET MARKET

Factor	Target market
Investment Objective	The Company expects that an investment in Unquoted Options will be suitable to investors who wish to gain exposure to equities in a small-cap pharmaceutical, biotechnology & life sciences company listed on the Australian Securities Exchange (ASX).
Investment Timeframe	The target market of investors will take a short to long term outlook on their investment. Investors with a short-term outlook for their investment will benefit from an ability to exercise Unquoted Options and trade the underlying Shares issued on exercise should the exercise price of the Unquoted Options be lower than the trading price of Shares. Investors with a medium-term outlook will benefit from an ability to exercise the Unquoted Options within the 4 year term of the Unquoted Options and increase their shareholding and

	<p>exposure to the potential upside in the Company's Shares into the future.</p> <p>Given the need to pay the exercise price in order to acquire Shares, Investors in the target market are in a financial position that is sufficient for them to invest their funds over a 4 year time horizon should they wish to exercise their Unquoted Options. Any decision to exercise the Unquoted Options is likely to be based on the trading price of the Shares.</p>
Investment Metrics	<p>While the Company does not have an established eligibility framework for investors based on metrics such as age, expected return or volatility, it is expected that the target market of investors will be able to withstand potential fluctuations in the value of their investment.</p> <p>An exercise price is required to be paid to acquire shares on exercise of Unquoted Options. As such, the capacity to realise the underlying value of the Unquoted Options would require that they be exercised on or before the expiry date. Investors in the target market will need to be in a financial position to have sufficient available funds so as to facilitate an exercise of the Unquoted Options prior to the expiry date. Prior to the expiry date, investors' ability to liquidate the Unquoted Options may be limited by a lack of liquidity in the trading of Shares and the price of the Shares.</p> <p>The Unquoted Options offer no guaranteed income or capital protection.</p>
Risk	<p>The Company considers that an investment in the Unquoted Options is highly speculative, such that an investment in the Company is not appropriate for an investor who would not be able to bear a loss of some or all of the investment. Investors should also have a sufficient level of financial literacy and resources (either alone or in conjunction with an appropriate adviser) to understand and appreciate the risks of investing in Unquoted Options as an asset class generally and the more specific risks of investing in an Australian listed in an Australian listed pharmaceuticals, biotechnology and life sciences company.</p>

2. DISTRIBUTION CONDITIONS

The offer of Unquoted Options under the Prospectus is being made to service providers that agreed to convert their existing debt into securities as specified in the Prospectus (**Eligible Shareholders**).

Any entitlement not taken up under the offer will not be issued. Eligible Shareholders may only subscribe for the number of Unquoted Options as specified in the Prospectus.

The Prospectus will include jurisdictional conditions on eligibility. The Company will also include on its web landing page for the offer of Unquoted Options a copy of this TMD and require that retail clients confirm that they meet the eligibility criteria of the expected target market outlined in this TMD before they apply for Unquoted Options.

The Company considers that these distribution conditions will ensure that persons who invest in Unquoted Options fall within the target market in circumstances where personal advice is not being provided to those persons by the Company.

3. REVIEW TRIGGERS

The Unquoted Options are being offered for a limited offer period set out in the Prospectus, after the conclusion of which the Unquoted Options will no longer be available for investment by way of issue. It follows that the TMD will only apply in the period between the commencement of the offer of the Unquoted Options and the issue of the Unquoted Options shortly after the close of the Offer (**Offer Period**).

To allow the Company to determine whether circumstances exist that indicate this TMD is no longer appropriate to the Unquoted Options and should be reviewed, the following review triggers apply for the Offer Period:

- (a) a new offer of Unquoted Options that requires preparation of a disclosure document is made after completion of the Offer Period;
- (b) any event or circumstance that would materially change a factor taken into account in making this TMD;
- (c) the existence of a significant dealing of the Unquoted Options that is not consistent with this TMD. The Company does not consider that an on-sale of the Unquoted Options on market is a significant dealing;
- (d) ASIC raises concerns with the Company regarding the adequacy of the design or distribution of the Unquoted Options or this TMD; and
- (e) material changes to the regulatory environment that applies to an investment in the Unquoted Options.

4. REVIEW PERIOD

If a review trigger occurs during the Offer Period, the Company will undertake a review of the TMD in light of the review trigger.

The Company will otherwise complete a review of the TMD immediately prior to the issue of Unquoted Options under the Offer.

5. INFORMATION REPORTING

The reporting requirements of all distributors is set out in the table below.

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
Whether the distributor received complaints about the Unquoted Options.	<ul style="list-style-type: none"> • For such time as the Offer Period remains open, within 10 business days after the end of each quarter. 	<ul style="list-style-type: none"> • The number of complaints received. • A summary of the nature of each complaint or a copy of each complaint.

Reporting requirement	Period for reporting to the Company by the distributor	Information to be provided
	<ul style="list-style-type: none"> Within 10 business days after the end of the Offer Period. 	
A significant dealing of the Unquoted Options that is not consistent with this TMD	As soon as reasonably practicable after the significant dealing occurs, but in any event no later than 10 business days after the significant dealing occurs.	<ul style="list-style-type: none"> Details of the significant dealing. Reasons why the distributor considers that the significant dealing is not consistent with this TMD.
A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.	Within 10 business days after the end of the close of the offer of Unquoted Options in accordance with the Prospectus.	A summary of the steps taken by the distributor to ensure that its conduct was consistent with this TMD.

6. CONTACT DETAILS

Contact details in respect of this TMD for the Company are:

Erlyn Dawson
Joint Company Secretary
Phone: +61 8 9389 3180
Email: info@cresopharma.com